Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Abrahams, Katherine A ^a   Cox, Jonathan A G ^b   Fütterer, Klaus ^a   Rullas, Joaquín ^c   Ortega Muro, Fátima ^c   Loman, Nicholas J ^a   Moynihan, Patrick J ^a   Pérez Herrán, Esther ^c   Jiménez, Elena ^c   Esquivias, Jorge ^c   Barros, David ^c   Ballell, Lluís ^c   Alemparte, Carlos ^c   Besra, Gurdyal S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

^c GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; ENZYME INHIBITOR; SULFOLANE; THIOPHENE DERIVATIVE; TRYPTOPHAN SYNTHASE; TUBERCULOSTATIC AGENT;

ANTAGONISTS AND INHIBITORS; ANTIBIOTIC RESISTANCE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MOLECULAR MODEL; MUTATION; MYCOBACTERIUM; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MUTATION; MYCOBACTERIUM; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES; TRYPTOPHAN SYNTHASE;

EID: 85028393942     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-09642-y     Document Type: Article

References (36)

1. Hingley-Wilson, S. M., Sambandamurthy, V. K. & Jacobs, W. R. Jr. Survival perspectives from the world's most successful pathogen. Mycobacterium tuberculosis. Nat. Immunol 4, 949-955 (2003).
2. World Health Organization. Global tuberculosis report. World Health Organisation, Geneva, Switzerland (2016).
3. Banerjee, A. et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263, 227-230 (1994).
4. Belanger, A. E. et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc. Natl Acad. Sci. USA 93, 11919-11924 (1996).
5. Campbell, E. A. et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 104, 901-912 (2001).
6. Zhang, Y., Shi, W., Zhang, W. & Mitchison, D. Mechanisms of pyrazinamide action and resistance. Microbiol spect 2, doi:10.1128/ microbiolspec.MGM2-0023-2013 (2014).
7. Ballell, L. et al. Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. ChemMedChem 8, 313-321 (2013).
8. Rebollo-Lopez, M. J. et al. Release of 50 new, drug-like compounds and their computational target predictions for open source antitubercular drug discovery. PloS one 10, e0142293, doi:10.1371/journal.pone.0142293 (2015).
9. Young, R. J., Green, D. V., Luscombe, C. N. & Hill, A. P. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug discov. today 16, 822-830 (2011).
10. Abrahams, K. A. et al. Identification of KasA as the cellular target of an anti-tubercular scaffold. Nat. commun. 7, 12581, doi:10.1038/ ncomms12581 (2016).
11. Abrahams, K. A. et al. Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS One 7, e52951, doi:10.1371/journal.pone.0052951 (2012).
12. Gurcha, S. S. et al. Biochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug target. PloS one 9, e113568, doi:10.1371/journal.pone.0113568 (2014).
13. Gouzy, A. et al. Mycobacterium tuberculosis exploits asparagine to assimilate nitrogen and resist acid stress during infection. PLoS pathog. 10, e1003928, doi:10.1371/journal.ppat.1003928 (2014).
14. Schneider, T. R. et al. Loop closure and intersubunit communication in tryptophan synthase. Biochemistry 37, 5394-5406 (1998).
15. Shen, H. et al. Characterization of the putative tryptophan synthase beta-subunit from Mycobacterium tuberculosis. Acta Biochim. Biophys. Sin. 41, 379-388 (2009).
16. Dunn, M. F., Niks, D., Ngo, H., Barends, T. R. & Schlichting, I. Tryptophan synthase: the workings of a channeling nanomachine. Trends Biochem. Sci. 33, 254-264 (2008).
17. Cox, J. A. G. et al. THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria. Nat. Microbio. 1, doi:10.1038/nmicrobiol.2015.6 (2016).
18. Mugumbate, G. et al. Mycobacterial dihydrofolate reductase inhibitors identified using chemogenomic methods and in vitro validation. PLoS One 10, e0121492, doi:10.1371/journal.pone.0121492 (2015).
19. Cox, J. A. et al. Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen. Scientific reports 6, 38986, doi:10.1038/srep38986 (2016).
20. Pan, P., Woehl, E. & Dunn, M. F. Protein architecture, dynamics and allostery in tryptophan synthase channeling. Trends Biochem. Sci. 22, 22-27 (1997).
21. Bahar, I. & Jernigan, R. L. Cooperative fluctuations and subunit communication in tryptophan synthase. Biochemistry 38, 3478-3490, doi:10.1021/bi982697v (1999).
22. Weyand, M. & Schlichting, I. Structural basis for the impaired channeling and allosteric inter-subunit communication in the beta A169L/beta C170W mutant of tryptophan synthase. J. Biol. Chem. 275, 41058-41063 (2000).
23. Qualls, J. E. & Murray, P. J. Immunometabolism within the tuberculosis granuloma: amino acids, hypoxia, and cellular respiration. Semin. Immunopathol. 38, 139-152 (2016).
24. Ryndak, M. B., Singh, K. K., Peng, Z. & Laal, S. Transcriptional profile of Mycobacterium tuberculosis replicating in type II alveolar epithelial cells. PloS one 10, e0123745, doi:10.1371/journal.pone.0123745 (2015).
25. Grandoni, J. A., Marta, P. T. & Schloss, J. V. Inhibitors of branched-chain amino acid biosynthesis as potential antituberculosis agents. J. Antimicrob. Chemother. 42, 475-482 (1998).
26. Studier, F. W. Protein production by auto-induction in high density shaking cultures. Protein expression and purification 41, 207-234 (2005).
27. Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
28. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235-242 (2011).
29. McCoy, A. J. Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr. D Biol. Crystallogr 63, 32-41 (2007).
30. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
31. Buller, A. R. et al. Directed evolution of the tryptophan synthase beta-subunit for stand-alone function recapitulates allosteric activation. Proc. Natl Acad. Sci. USA 112, 14599-14604 (2015).
32. Wellington, S. et al. A small-molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase. Nat. Chem. Biol, doi:10.1038/nchembio.2420 (2017).
33. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
34. Rullas, J. et al. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob. Agents Chemother. 54, 2262-2264 (2010).
35. Blanco-Ruano, D. et al. Antimicrobial susceptibility testing for Mycobacterium sp. Methods Mol. Biol. 1285, 257-268 (2015).
36. Ward, S. E. et al. Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators. J.Med. Chem. 54, 78-94 (2011).